| (1) |
Cooper DS 1998 Antithyroid drugs for the treatment
of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North
Am 27: 225-247 |
| (2) |
Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton
RN 1996 Consensus statement for good practice and audit measures in
the management of hyperthyroidism and hypothyroidism. BMJ 313: 539-544 |
| (3) |
Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman
LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment
guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 273:
808-812 |
| (4) |
2002 American Association of Clinical Endocrinologists
medical guidelines for clinical practice for the evaluation and treatment
of hyperthyroidism and hypothyroidism. Endocr Prac 8: 457-467 |
| (5) |
Siwek J, Gourlay ML, Slawson DC, Shaughnessy AF
2002 How to write an evidence-based clinical review article. Am Fam Physician
65: 251-258 |
| (6) |
Leech NL, Dayan CM 1998 Controversies in the management of Graves'
disease. Clin Endocrinol (Oxf) 49: 273-280 |
| (7) |
Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari
M, Fujishima M 1987 Reevaluation of the effects of methylmercaptoimidazole
and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol
Metab 65: 719-723 |
| (8) |
Nicholas WC, Fischer RG, Stevenson RA, Bass JD 1995 Single daily
dose of methimazole compared to every 8 hours propylthiouracil in the treatment
of hyperthyroidism. South Med J 88: 973-976 |
| (9) |
Kallner G, Vitols S, Ljunggren JG 1996 Comparison
of standardized initial doses of two antithyroid drugs in the treatment
of Graves' disease. J Intern Med 239: 525-529 |
| (10) |
Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant
W, Vichayanrat A 2000 Efficacy of single daily dosage of methimazole
vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf)
54: 385-390 |
| (11) |
Cooper DS 1999 The side-effects of antithyroid
drugs. Endocrinologist 9: 457-467 |
| (12) |
Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah
CS 1989 Adverse effects related to thionamide drugs and their dose regimen.
Am J Med Sci 297: 216-219 |
| (13) |
Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels
GH, Molitch ME, Ridgway EC 1983 Agranulocytosis associated with antithyroid
drugs. Effects of patient age and drug dose. Ann Intern Med 98: 26-29 |
| (14) |
Messina M, Milani P, Gentile L, Monaco A, Brossa
C, Porta M, Camanni F 1987 Initial treatment of thyrotoxic Graves' disease
with methimazole: a randomized trial comparing different dosages. J Endocrinol
Invest 10: 291-295 |
| (15) |
Solomon B, Glinoer D, Lagasse R, Wartofsky L
1990 Current trends in the management of Graves' disease. J Clin Endocrinol
Metab 70: 1518-1524 |
| (16) |
Tuttle RM, Patience T, Budd S 1995 Treatment with propylthiouracil
before radioactive iodine therapy is associated with a higher treatment
failure rate than therapy with radioactive iodine alone in Graves' disease.
Thyroid 5: 243-247 |
| (17) |
Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience
T 1997 The effect of propylthiouracil on subsequent radioactive iodine
therapy in Graves' disease. Clin Endocrinol (Oxf) 47: 425-430 |
| (18) |
Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR
1998 Pretreatment with propylthiouracil but not methimazole reduces the
therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol
Metab 83: 685-687 |
| (19) |
Turton DB, Silverman ED, Shakir KM 1998 Time
interval between the last dose of propylthiouracil and I-131 therapy influences
cure rates in hyperthyroidism caused by Graves' disease. Clin Nucl Med 23:
810-814 |
| (20) |
Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci
E, Fenzi GF, PincheraA 1990 Areappraisal of the role of methimazole
and other factors on the efficacy and outcome of radioiodine therapy of
Graves' hyperthyroidism. J Endocrinol Invest 13: 513-520 |
| (21) |
Andrade VA, Gross JL, Maia AL 2001 Effect of
methimazole pretreatment on the efficacy of radioactive iodine therapy in
Graves' hyperthyroidism: one-year follow-up of a prospective randomized
study. J Clin Endocrinol Metab 86: 3488-3493 |
| (22) |
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS 2002 The effect
of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism:
a randomized clinical trial. Thyroid 12: 135-139 |
| (23) |
Crooks J, BuchananWW,Wayne EJ, MacDonald E 1960
Effect of pretreatment with methythiouracil on results of 131I therapy.
Br Med J 16: 151-154 |
| (24) |
Tamai H, Nakagawa T, Fukino O, Ohsako N, Shinzato R, Suematsu H, Kuma
K, Matsuzuka F, Nagataki S 1980 Thionamide therapy in Graves' disease:
relation of relapse rate to duration of therapy. Ann Intern Med 92: 488-490 |
| (25) |
Lippe BM, Landaw EM, Kaplan SA 1987 Hyperthyroidism
in children treated with long term medical therapy: twenty-five percent
remission every two years. J Clin Endocrinol Metab 64: 1241-1245 |
| (26) |
Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le
Guerrier AM, Delambre C, Derennes V 1990 Antithyroid drugs and Graves'
disease: a prospective randomized evaluation of the efficacy of treatment
duration. J Clin Endocrinol Metab 70: 675-679 |
| (27) |
Garcia-Mayor RVG, Paramo C, Luna-Cano R, Perez Mendez
LF, Galofre JC, Andrade A 1992 Antithyroid drug and Graves' hyperthyroidism.
Significance of treatment duration and TRAb determination on lasting remission.
J Endocrinol Invest 15: 815-820 |
| (28) |
Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM 1994
Treatment of Graves' disease with the block-replace regimen of antithyroid
drugs: the effect of treatment duration and immunogenetic susceptibility
on relapse. Q J Med 87: 337-341 |
| (29) |
Maugendre D, Gatel A, Campion L, Massart C, Guilhem
I, Lorcy Y, Lescouarch J, Herry JY, Allannic H1999 Antithyroid drugs
and Graves' disease-prospective randomized assessment of long-term treatment.
Clin Endocrinol (Oxf) 50: 127-132 |
| (30) |
Weetman AP 1994 The immunomodulatory effects of antithyroid drugs.
Thyroid 4: 145-146 |
| (31) |
Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues
HF, Werner MC, Farah CS, Reis LC 1983 Comparison of effects of high
and low dosage regimens of antithyroid drugs in the management of Graves'
hyperthyroidism. J Clin Endocrinol Metab 57: 563-570 |
| (32) |
Jorde R, Ytre-Arne K, Stormer J, Sundsfjord J 1995 Short-term treatment
of Graves' disease with methimazole in high versus low doses. J Intern Med
238: 161-165 |
| (33) |
Wilson R, Buchanan L, Fraser W, McKillop J, Thomson
J 1996 Do higher doses of carbimazole improve remission in Graves' disease?
QJM 89: 381-385 |
| (34) |
Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmarti
A 1997 Medical therapy of Graves' disease: does thyroxine prevent recurrence
of hyperthyroidism? J Clin Endocrinol Metab 82: 2410-2413 |
| (35) |
Benker G, Reinwein D, Kahaly G, Tegler L, Alexander
WD, Fassbinder J, Hirche H 1998 Is there a methimazole dose effect on
remission rate in Graves' disease? Results from a long-term prospective
study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism
with Antithyroid Drugs. Clin Endocrinol (Oxf) 49: 451-457 |
| (36) |
Grebe SKG, Feek CM, Ford HC, Fagerstrom JN, Cordwell DP, Delahunt JW,
Toomath RJ 1998 A randomized trial of short-term treatment of Graves'
disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
Clin Endocrinol (Oxf) 48: 585-592 |
| (37) |
Reinwein D, Benker G, Lazarus JH, Alexander WD
1993 A prospective randomized trial of antithyroid drug dose in Graves'
disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
J Clin Endocrinol Metab 76: 1516-1521 |
| (38) |
Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ 1996 A comparison
of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism.
Clin Endocrinol (Oxf) 45: 511-516 |
| (39) |
Hashizume K, Ichikawa I, Sakurai A, Suzuki S, Takeda
T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T 1991 Administration of
thyroxine in treated Graves' disease. N Engl J Med 324: 947-953 |
| (40) |
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A 1996 Lack
of effect of thyroxine in patients with Graves' hyperthyroidism who are
treated with an antithyroid drug. N Engl J Med 334: 220-224 |
| (41) |
Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner
ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York
SE 1996 Effect of methimazole with or without exogenous l-thyroxine
on serum concentrations of thyrotropin (TSH) receptor antibodies in patients
with Graves' disease. J Clin Endocrinol Metab 81: 3283-3288 |
| (42) |
Pfeilschifter J, Zeigler R 1997 Suppression of serum thyrotropin
with thyroxine in patients with Graves' disease: effects on recurrence hyperthyroidism
and thyroid volume. Eur J Endocrinol 136: 81-86 |
| (43) |
Pujol P, Osman A, Grabar S, Daures JP, Galtier-Dereure
F, Boegner C, Baldet L, Raye R, Bringer J, Jaffiol C 1998 TSH suppression
combined with carbimazole for Graves' disease: effect on remission and relapse
rates. Clin Endocrinol (Oxf) 48: 635-640 |
| (44) |
Raber W, Kmen E, Waldhausl W, Vierhapper H 2000 Medical therapy
of Graves' disease: effect on remission rates of methimazole alone and in
combination with triiodothyronine. Eur J Endocrinol 142: 117-124 |
| (45) |
Glinoer D, de Nayer P, Bex M 2001 Effects of
l-thyroxine administration, TSH-receptor antibodies and smoking on the risk
of recurrence in Graves' hyperthyroidism treated with antithyroid drugs:
a double-blind prospective randomized study. Eur J Endocrinol 144: 475-483 |
| (46) |
Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye
ES, Lien EA, Aanderud S 2002 Predictors of outcome and comparison of
different drug regimens for the prevention of relapse in patients with Graves'
disease. Eur J Endocrinol 147: 583-589 |
| (47) |
Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I,
Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche
H, Mann K 2002 Relapse of Graves' disease after successful outcome of
antithyroid drug therapy: results of a randomized study on the use of thyroxine.
Thyroid 12: 1119-1128 |
| (48) |
Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi
R, Martino E, Pinchera A 1997 Clinical features of patients with Graves'
disease undergoing remission after antithyroid drug treatment. Thyroid 7:
369-375 |
| (49) |
Chowdhury TA, Dyer PH 1998 Clinical, biochemical
and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis
treated with antithyroid drugs. J Intern Med 244: 293-297 |
| (50) |
Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn
JA 2000 Age and gender predict the outcome of treatment for Graves'
hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042 |
| (51) |
Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita
T, Kubo C, Kuma K 1995 A study of untreated Graves' patients with undetectable
TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
Clin Endocrinol (Oxf) 43: 551-556 |
| (52) |
Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P
1998 The prognostic value of thyrotropin receptor antibody measurement in
the early stages of treatment of Graves' disease with antithyroid drugs.
Thyroid 8: 119-124 |
| (53) |
Shafer RB, Nuttall FQ 1975 Acute changes in thyroid
function in patients treated with radioactive iodine. Lancet 2: 635-637 |
| (54) |
Tamagna EI, Levine GA, Hershman JM 1979 Thyroid-hormone concentrations
after radioiodine therapy for hyperthyroidism. J Nucl Med 20: 387-391 |
| (55) |
Stensvold AD, Jorde R, Sundsfjord J 1997 Late
and transient increases in free T4 after radioiodine treatment for Graves'
disease. J Endocrinol Invest 20: 580-584 |
| (56) |
Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R
2001 The effect of antithyroid drug pretreatment on acute changes in thyroid
hormone levels after (131) I ablation for Graves' disease. J Clin Endocrinol
Metab 86: 3016-3021 |
| (57) |
Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic
D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A 1998 Outcome
of thyroid function in Graves' patients treated with radioiodine: role of
thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced
thyroid damage. J Clin Endocrinol Metab 83: 40-46 |
| (58) |
McDermott MT, Kidd GS, Dodson Jr LE, Hofeldt FD 1983 Radioiodineinduced
thyroid storm. Case report and literature review. Am J Med 75: 353-359 |
| (59) |
Aro A, Huttunen JK, Lamberg BA, Pelkonen R, Ikkala
E, Kuusisto A, Rissanen V, Salmi J, Tervonen S 1981 Comparison of propranolol
and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism. Acta
Endocrinol (Copenh) 96: 321-327 |
| (60) |
Andrade VA, Gross JL, Maia AL 1999 Effect of methimazole pretreatment
on serum thyroid hormone levels after radioiodine treatment in Graves' hyperthyroidism.
J Clin Endocrinol Metab 84: 4012-4016 |
| (61) |
Burch HB, Solomon BL, Wartofsky L, Burman KD
1994 Discontinuing antithyroid drug therapy before ablation with radioiodine
in Graves' disease. Ann Intern Med 121: 553-559 |
| (62) |
Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino
F, Rossi G, Lippi F, Pinchera A, Martino E 2002 Treatment with lithium
prevents serum thyroid hormone increase after thionamide withdrawal and
radioiodine therapy in patients with Graves' disease. J Clin Endocrinol
Metab 87: 4490-4495 |
| (63) |
Gamstedt A, Wadman B, Karlsson A 1986 Methimazole,
but not betamethasone, prevents 131I treatment-induced rises in thyrotropin
receptor autoantibodies in hyperthyroid Graves' disease. J Clin Endocrinol
Metab 62: 773-777 |
| (64) |
Kung AW, Yau CC, Cheng A 1994 The incidence of ophthalmopathy after
radioiodine therapy for Graves' disease: prognostic factors and the role
of methimazole. J Clin Endocrinol Metab 79: 542-546 |
| (65) |
Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N,
Tani JI, Nakagawa Y, Ito S 1999 Antithyroid drugs inhibit radioiodine-induced
increases in thyroid autoantibodies in hyperthyroid Graves' disease. Thyroid
9: 775-779 |
| (66) |
Bazzi MN, Bagchi N 1993 Adjunctive treatment with propylthiouracil
or iodine following radioiodine therapy for Graves' disease. Thyroid 3:
269-272 |
| (67) |
Kung AW, Yau CC, Cheng AC 1995 The action of
methimazole and lthyroxine in radioiodine therapy: a prospective study on
the incidence of hypothyroidism. Thyroid 5: 7-12 |
| (68) |
Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori
A, Manetti L, Rossi G, Pinchera A, Martino E 1999 Comparison of radioiodine
with radioiodine plus lithium in the treatment of Graves' hyperthyroidism.
J Clin Endocrinol Metab 84: 499-503 |
| (69) |
Bal CS, Kumar A, Pandey RM 2002 A randomized
controlled trial to evaluate the adjuvant effect of lithium on radioiodine
treatment of hyperthyroidism. Thyroid 12: 399-405 |